The FDA designates Abeona Therapeutics' (NASDAQ:ABEO) Orphan Drug-tagged EB-101, a Breakthrough Therapy for the treatment of epidermolysis bullosa. ABEO shares up more than 40% since added to my portfolio. I've decided to take profits on ABEO.
CAR-T developer Bellicum Pharmaceuticals (NASDAQ:BLCM) is up after Gilead's announced $11.9B takeover of Kite Pharma. Its lead candidate is Phase 1/2-stage BPX-501. Shares up almost 40% since added to my portfolio. I've decided to take profits on BLCM.
With the cash coming from BLCM and ABEO I go for Amicus (NASDAQ:FOLD) and increase my holdings.
My Portfolio has been updated with today's closing prices.